ACLARION, INC. Research and Development Expense
ACLARION, INC. (ACON) reported Research and Development Expense of $297.07 thousand for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:ResearchAndDevelopmentExpense · last filed 2026-08-06
- ACLARION, INC. research and development expense for the quarter ending 2026-06-30 was $297.07K, a 9.85% increase year-over-year.
- ACLARION, INC. research and development expense for the quarter ending 2026-03-31 was $315.42K, a 59.15% increase year-over-year.
- ACLARION, INC. research and development expense for the quarter ending 2025-12-31 was $263.13K, a 4.49% increase year-over-year.
- ACLARION, INC. research and development expense for the quarter ending 2025-09-30 was $302.04K, a 54.26% increase year-over-year.
- ACLARION, INC. research and development expense for fiscal 2025 was $1.03M, a 16.32% increase from fiscal 2024.
- ACLARION, INC. research and development expense for fiscal 2024 was $888.77K, a 1.77% increase from fiscal 2023.
- ACLARION, INC. research and development expense for fiscal 2023 was $873.34K, a 18.23% decline from fiscal 2022.
- ACLARION, INC. research and development expense for fiscal 2022 was $1.07M, a 35.56% increase from fiscal 2021.
| Period end | Research and Development Expense 3 month | Research and Development Expense 6 month | Research and Development Expense 9 month | Research and Development Expense 12 month | Research and Development Expense 12 month as first filed |
|---|---|---|---|---|---|
| 2026-06-30 | $297.07K 10-Q · filed 2026-08-06 | $612.49K 10-Q · filed 2026-08-06 | $875.62K derived: sum of 3 quarters · filed 2026-08-06 | $1.18M derived: sum of 4 quarters · filed 2026-08-06 | |
| 2026-03-31 | $315.42K 10-Q · filed 2026-05-13 | $578.55K derived: sum of 2 quarters · filed 2026-05-13 | $880.58K derived: sum of 3 quarters · filed 2026-05-13 | $1.15M derived: sum of 4 quarters · filed 2026-08-06 | |
| 2025-12-31 | $263.13K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-18 | $565.17K derived: sum of 2 quarters · filed 2026-03-18 | $835.60K derived: sum of 3 quarters · filed 2026-08-06 | $1.03M 10-K · filed 2026-03-18 | |
| 2025-09-30 | $302.04K 10-Q · filed 2025-11-12 | $572.47K derived: sum of 2 quarters · filed 2026-08-06 | $770.66K 10-Q · filed 2025-11-12 | $1.02M derived: sum of 4 quarters · filed 2026-08-06 | |
| 2025-06-30 | $270.43K 10-Q · filed 2026-08-06 | $468.62K 10-Q · filed 2026-08-06 | $720.45K derived: sum of 3 quarters · filed 2026-08-06 | $916.25K derived: sum of 4 quarters · filed 2026-08-06 | |
| 2025-03-31 | $198.19K 10-Q · filed 2026-05-13 | $450.02K derived: sum of 2 quarters · filed 2026-05-13 | $645.81K derived: sum of 3 quarters · filed 2026-05-13 | $847.91K derived: sum of 4 quarters · filed 2026-05-13 | |
| 2024-12-31 | $251.83K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-18 | $447.62K derived: sum of 2 quarters · filed 2026-03-18 | $649.73K derived: sum of 3 quarters · filed 2026-03-18 | $888.77K 10-K · filed 2026-03-18 | |
| 2024-09-30 | $195.80K 10-Q · filed 2025-11-12 | $397.90K derived: sum of 2 quarters · filed 2025-11-12 | $636.94K 10-Q · filed 2025-11-12 | $857.62K derived: sum of 4 quarters · filed 2025-11-12 | |
| 2024-06-30 | $202.10K 10-Q · filed 2025-08-14 | $441.14K 10-Q · filed 2025-08-14 | $661.82K derived: sum of 3 quarters · filed 2025-08-14 | $860.08K derived: sum of 4 quarters · filed 2025-08-14 | |
| 2024-03-31 | $239.04K 10-Q · filed 2025-05-15 | $459.72K derived: sum of 2 quarters · filed 2025-05-15 | $657.97K derived: sum of 3 quarters · filed 2025-05-15 | $907.98K derived: sum of 4 quarters · filed 2025-05-15 | |
| 2023-12-31 | $220.68K derived: 10-K 12 month − 10-Q 9 month · filed 2025-04-09 | $418.93K derived: sum of 2 quarters · filed 2025-04-09 | $668.94K derived: sum of 3 quarters · filed 2025-04-09 | $873.34K 10-K · filed 2025-04-09 | |
| 2023-09-30 | $198.25K 10-Q · filed 2024-11-14 | $448.26K derived: sum of 2 quarters · filed 2024-11-14 | $652.66K 10-Q · filed 2024-11-14 | $871.65K derived: sum of 4 quarters · filed 2024-11-14 | |
| 2023-06-30 | $250.01K 10-Q · filed 2024-08-14 | $454.40K 10-Q · filed 2024-08-14 | $673.40K derived: sum of 3 quarters · filed 2024-08-14 | $964.37K derived: sum of 4 quarters · filed 2024-08-14 | |
| 2023-03-31 | $204.40K 10-Q · filed 2024-05-15 | $423.40K derived: sum of 2 quarters · filed 2024-05-15 | $714.36K derived: sum of 3 quarters · filed 2024-05-15 | $1.07M derived: sum of 4 quarters · filed 2024-05-15 | |
| 2022-12-31 | $219.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-28 | $509.96K derived: sum of 2 quarters · filed 2024-03-28 | $863.19K derived: sum of 3 quarters · filed 2024-03-28 | $1.07M 10-K · filed 2024-03-28 | $1.09M 10-K · filed 2023-02-27 |
| 2022-09-30 | $290.97K 10-Q · filed 2023-11-14 | $644.19K derived: sum of 2 quarters · filed 2023-11-14 | $849.00K 10-Q · filed 2023-11-14 | $1.03M derived: sum of 4 quarters · filed 2023-11-14 | |
| 2022-06-30 | $353.23K 10-Q · filed 2023-08-25 | $558.03K 10-Q · filed 2023-08-25 | $740.13K derived: sum of 3 quarters · filed 2023-08-25 | $1.02M derived: sum of 4 quarters · filed 2023-08-25 | |
| 2022-03-31 | $204.80K 10-Q · filed 2023-07-03 | $386.90K derived: sum of 2 quarters · filed 2023-07-03 | $662.19K derived: sum of 3 quarters · filed 2023-07-03 | $824.90K derived: sum of 4 quarters · filed 2023-07-03 | |
| 2021-12-31 | $182.10K derived: 10-K/A 12 month − 10-Q 9 month · filed 2023-06-12 | $457.38K derived: sum of 2 quarters · filed 2023-06-12 | $620.10K derived: sum of 3 quarters · filed 2023-06-12 | $787.85K 10-K/A · filed 2023-06-12 | |
| 2021-09-30 | $275.28K 10-Q · filed 2022-11-14 | $438.00K derived: sum of 2 quarters · filed 2022-11-14 | $605.75K 10-Q · filed 2022-11-14 | ||
| 2021-06-30 | $162.71K 10-Q · filed 2022-08-15 | $330.46K 10-Q · filed 2022-08-15 | |||
| 2021-03-31 | $167.75K 10-Q · filed 2022-06-06 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Advanced Biomed Inc. (ADVB) | $0.009B | ||
| AMERICAN SHARED HOSPITAL SERVICES (AMS) | United States | $0.010B | -5.64 |
| BioNexus Gene Lab Corp (BGLC) | $0.004B | ||
| SERA PROGNOSTICS, INC. (SERA) | United States | $0.062B | -5.75 |
| Freenome, Inc. (FRNM) | United States | $0.143B | |
| EXAGEN INC. (XGN) | United States | $0.212B | -5.95 |
| BIODESIX INC (BDSX) | United States | $0.312B | |
| Fulgent Genetics, Inc. (FLGT) | United States | $0.593B | -6.70 |
| Lumexa Imaging Holdings, Inc. (LMRI) | United States | $0.951B | |
| CASTLE BIOSCIENCES INC (CSTL) | United States | $1.074B | -37.45 |